Analyzing public datasets, immunohistochemical studies, and our own cohorts, we showed that BiP protein expression is associated with prognosis clinicopathological factors and further validation should establish its potential as an immunohistochemical marker to be used in breast cancer diagnostics. Here, HSPA5 is linked to breast cancer.